References

1. https://www.merckmanuals.com/professional/hepatic-and-biliarydisorders/approach-to-the-patient-with-liver-disease/nonalcoholicsteatohepatitis-nash#derugsInArticle [View]
2. https://www.uptodate.com/contents/epidemiology-clinical-features-anddiagnosis-of-nonalcoholic-fatty-liver-disease-in-adults [View]
3. https://www.ncbi.nlm.nih.gov/pubmed/28195177 [CrossRef] [Google Scholar] [PubMed]
4. https://www.merckmanuals.com/professional/hepatic-and-biliarydisorders/approach-to-the-patient-with-liver-disease/nonalcoholicsteatohepatitis-nash#derugsInArticle [View]
5. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nashchildren [View]
6. https://rarediseases.info.nih.gov/diseases/6430/nonalcoholicsteatohepatitis
7. https://www.xconomy.com/boston/2018/10/09/eying-nash-glympse-raises-22m-to-test-disease-detection-nanotech/?utm_source=Xconomy&utm_ c a m p a i g n = 8 8 1 f e 4 d 7 0 a - N E W S L E T T E R _ E X O M E & u t m _medium=email&utm_term=0_2aa91c0bc9-881fe4d70a-288454541&mc_cid=881fe4d70a&mc_eid=922fe2659c [View]
8. https://www.uptodate.com/contents/epidemiology-clinical-features-anddiagnosis-of-nonalcoholic-fatty-liver-disease-in-adults [View]
9. https://www.ncbi.nlm.nih.gov/pubmed/28195177
10. https://www.interceptpharma.com/our-focus/nash/ [View]
11. https://rarediseases.info.nih.gov/diseases/6430/nonalcoholicsteatohepatitis
12. https://www.merckmanuals.com/professional/hepatic-and-biliarydisorders/approach-to-the-patient-with-liver-disease/nonalcoholicsteatohepatitis-nash#derugsInArticle [View]
13. https://www.xconomy.com/boston/2018/10/09/eying-nash-glympse-raises-22m-to-test-disease-detection-nanotech/?utm_source=Xconomy&utm_c a m p a i g n = 8 8 1 f e 4 d 7 0 a - N E W S L E T T E R _ E X O M E & u t m _medium=email&utm_term=0_2aa91c0bc9-881fe4d70a-288454541&mc_cid=881fe4d70a&mc_eid=922fe2659c [View]
14. https://rarediseases.info.nih.gov/diseases/6430/nonalcoholicsteatohepatitis
15. https://rarediseases.info.nih.gov/diseases/6430/nonalcoholicsteatohepatitis
16. https://www.merckmanuals.com/professional/hepatic-and-biliarydisorders/approach-to-the-patient-with-liver-disease/nonalcoholicsteatohepatitis-nash#derugsInArticlehttps://mysearch.avg.com/tab?sap=nt&rvt=1&pid=wtu&cid=&mid=81ae095519414a988a057c25b66d76aa&ds=avgsxa&v=4.3.9.7&lang=en-US&pr=&d=2018/04/14%2013:23:53&ud=&cmpid= [View]
17. https://rarediseases.info.nih.gov/diseases/6430/nonalcoholicsteatohepatitis
18. https://rarediseases.info.nih.gov/diseases/6430/nonalcoholicsteatohepatitis
19. https://www.diabetesselfmanagement.com/diabetes-resources/definitions/ ppar-agonists/ [View]
20. https://seekingalpha.com/article/4140520-science-behind-genfitselafibranor
21. http://www.selleckchem.com/products/elafibranor.html [View]
22. https://seekingalpha.com/article/4140520-science-behind-genfitselafibranor
23. ibid
24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293481/ [CrossRef] [Google Scholar] [PubMed]
25. ibid
26. ibid
27. https://www.nih.gov/news-events/news-releases/new-drug-common-liverdisease- improves-liver-health [View]
28. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/ clinical-trials [View]
29. http://www.genfit.com/press-release/genfit-new-preclinical-data-showselafibranor-inhibits-development-of-nafld-nash-related-cancer/ [View]
30. https://www.fiercebiotech.com/biotech/orbimed-launches-nash-focused-89bio-60m-series-a-rohan-palekar-as-ceo?mkt_tok=eyJpIjoiWWpFd09EUTJOR1l5TldJMiIsInQiOiJNanpHRVEzNU44dWZDM3pWcjJUaHJFYjZab UFSMUxDblhPUVQ5ZFpFN1wvZGZJbFBwQ2NZWmRHTUlybEwxbDJm Y0xON1U1QXdGSng5SG1tMFJaNUp5RW16UnBxRkg0NytTVGxGbVwv Y2VhNTdzb2ZCTTdUWENVUm9tbjZldlJieFR1In0%3D&mrkid=11119266 [View]
31. https://www.cnbc.com/2014/07/15/the-next-hepatitis-c-nash.html [View]